FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220657204> ?p ?o ?g. }

• W4220657204 endingPage "1039" @default.
• W4220657204 startingPage "1037" @default.
• W4220657204 abstract "Among the different SARS-CoV-2 variants of concern [[1]Harvey W.T. Carabelli A.M. Jackson B. Gupta R.K. Thomson E.C. Harrison E.M. et al.SARS-CoV-2 variants, spike mutations and immune escape.Nat Rev Microbiol. 2021; 19: 409-424Crossref PubMed Scopus (1517) Google Scholar], Delta and Omicron currently account for the vast majority of cases worldwide, with the latter rapidly replacing the former in many countries [[2]Hodcroft E. CoVariants: SARS-CoV-2 mutations and variants of interest; C2021.https://covariants.org/Google Scholar]. Notably, Omicron is the most divergent from the wild-type B.1 strain, with 15 amino acid changes in the receptor-binding domain of the spike protein, the major target of neutralizing antibodies. Indeed, Omicron partly escapes natural or vaccine-elicited immunity [[3]Dejnirattisai W. Shaw R.H. Supasa P. Liu C. Stuart A.S. Pollard A.J. et al.Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum.Lancet. 2022; 399: 234-236Abstract Full Text Full Text PDF PubMed Scopus (186) Google Scholar] and can decrease the efficacy of currently licensed therapeutic monoclonal antibodies (mAbs) [[4]Cameroni E. Bowen J.E. Rosen L.E. Saliba C. Zepeda S.K. Culap K. et al.Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.Nature. 2022; 602: 664-670Crossref PubMed Scopus (506) Google Scholar,[5]VanBlargan L.A. Errico J.M. Halfmann P.J. Zost S.J. Crowe Jr., J.E. Purcell L.A. et al.An infectious SARS-CoV-2 B.1.1.529 omicron virus escapes neutralization by therapeutic monoclonal antibodies.Nat Med. 2022; 19: 1-6Google Scholar]. We assessed the ex vivo inhibition of Omicron and Delta variants by sera obtained from unvaccinated patients treated with one of the three licensed mAb preparations, namely bamlanivimab/etesevimab, casirivimab/imdevimab, and sotrovimab. A pair of patient sera samples was collected, the first before (to exclude any prior neutralizing antibody (NtAb) activity) and the second 1 hour after mAbs infusion. The study was conducted in accordance with the Declaration of Helsinki and approved by the local ethics committee (Neutro-COVID observational study, protocol number 4069/21). Written informed consent was obtained from all the patients enrolled. The efficacy of the mAbs was assessed by a live virus neutralization assay against wild type (GISAID accession number EPI_ISL_2472896), Delta (EPI_ISL_2840619), the Omicron sublineage BA.1 (EPI_ISL_6777160), and the Delta sublineage AY.4.2 (EPI_ISL_6943992), recently detected in Italy [[6]Angeletti S. Giovanetti M. Fogolari M. Cella E. De Florio L. Lintas C. et al.SARS-CoV-2 AY.4.2 variant circulating in Italy: genomic preliminary insight.J Med Virol. 2022; 94: 1689-1692Crossref PubMed Scopus (8) Google Scholar] and carrying the additional Y145H and A222V spike substitutions (details of each viral stock are indicated in Table S1). NtAb titres were determined by a microneutralization live virus assay [[7]Vicenti I. Gatti F. Scaggiante R. Boccuto A. Zago D. Basso M. et al.Single-dose BNT162b2 mRNA COVID-19 vaccine significantly boosts neutralizing antibody response in health care workers recovering from asymptomatic or mild natural SARS-CoV-2 infection.Int J Infect Dis. 2021; 108: 176-178Abstract Full Text Full Text PDF PubMed Scopus (22) Google Scholar] and defined as the reciprocal value of the sample dilution that showed a 50% protection of virus-induced cytopathic effect (ID50). Statistical analyses were performed using IBM SPSS Statistics, version 20. Sera with ID50 < 10 were defined as negative and scored as 5 for statistical analysis. Data were expressed as median (IQR), as appropriate for the distribution of data based on the Shapiro-Wilk test for normality. The Kruskal-Wallis test followed by Mann-Whitney test post hoc analysis was used to compare independent groups, and the Friedman test followed by Wilcoxon rank sum test post hoc analysis was used to compare multiple paired data. Spearman analysis was used to measure the correlation between NtAb titres against the different variants. Of 30 patients studied (14 males, age 59 ± 18 years, full characteristics summarized in Table S2), one was asymptomatic and the others had mild symptoms such as cough (n = 19), fever (n = 17), headache (n = 13), gastrointestinal symptoms (n = 4), and dyspnoea (n = 2). Patients were randomly treated with bamlanivimab/etesevimab (n = 10), casirivimab/imdevimab (n = 10), or sotrovimab (n = 10), 3.5 ± 1.7 days from diagnosis. None of the patients required hospitalization. All preinfusion sera were negative for SARS-CoV-2 NtAb activity. In postinfusion sera, casirivimab/imdevimab, bamlanivimab/etesevimab, and sotrovimab showed activity against the wild-type variant (19,814 (17,459–23,471), 6792 (4736–8328), and 456 (259–592)), the Delta variant (58,858 (41,585–79,971), 12,145 (10,840–18,667), and 1023 (798–1134)), and Delta AY.4.2 (58,602 (42,941–82, 960), 11,067 (10,757–12,614), and 1333 (708–1714)). Notably, sotrovimab was the only active treatment against the Omicron variant (216 (118–233)) (Fig. 1). Within each individual treatment group, the NtAb titres to Delta and Delta AY.4.2 variants were significantly higher than those to wild type (p = 0.008 for AY.4.2 vs. wild type with sotrovimab; p = 0.005 for all other comparisons). NtAb titres to wild type, Delta, and Delta AY.4.2 variants were higher than those to Omicron within all individual treatment groups (p = 0.005 for all comparisons). Comparing treatments, casirivimab/imdevimab neutralizing titres were significantly higher than bamlanivimab/etesevimab and sotrovimab against wild type, Delta, and the Delta AY.4.2 variants, and bamlanivimab/etesevimab neutralizing titres were significantly higher than sotrovimab for the same variants (p < 0.001 for all comparisons). When considering all 30 postinfusion sera, a significant correlation was observed between NtAb titres to any pair of wild type, Delta, and Delta AY.4.2 variants (p < 0.001 for all comparisons), whereas NtAb titres to Omicron correlated significantly only to NtAb titres to wild-type virus (p = 0.009) (Fig. S1). A previous report documented in vitro inhibition of the Delta variant by the individual mAbs etesevimab, casirivimab, and imdevimab, but not bamlanivimab, at slightly higher levels compared with the wild-type B.1 virus [[8]Planas D. Veyer D. Baidaliuk A. Staropoli I. Guivel-Benhassine F. Rajah M.M. et al.Reduced sensitivity of SARS-CoV-2 variant delta to antibody neutralization.Nature. 2021; 596: 276-280Crossref PubMed Scopus (1237) Google Scholar]. Our study confirms these findings by testing the bamlanivimab/etesevimab and casirivimab/imdevimab cocktails in an ex vivo format. In addition, we demonstrated maintenance of activity against Delta AY.4.2 for the first time, implying that the additional Y145H and A222V mutations have no impact on neutralization by these mAbs preparations. Most importantly, our results support full escape of commonly used mAbs cocktails by the Omicron variant, as recently reported [[4]Cameroni E. Bowen J.E. Rosen L.E. Saliba C. Zepeda S.K. Culap K. et al.Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.Nature. 2022; 602: 664-670Crossref PubMed Scopus (506) Google Scholar], although sotrovimab appears to retain activity against all variants tested, including Omicron (albeit reduced by an average 2.7-fold in paired measurements), similar to what has been reported in the literature [[5]VanBlargan L.A. Errico J.M. Halfmann P.J. Zost S.J. Crowe Jr., J.E. Purcell L.A. et al.An infectious SARS-CoV-2 B.1.1.529 omicron virus escapes neutralization by therapeutic monoclonal antibodies.Nat Med. 2022; 19: 1-6Google Scholar,[9]Tzou P.L. Tao K. Nouhin J. Rhee S.Y. Hu B.D. Pai S. et al.Coronavirus Antiviral Research Database (CoV-RDB): an online database designed to facilitate comparisons between candidate anti-coronavirus compounds.Viruses. 2020; 12: 1006Crossref Scopus (43) Google Scholar]. Since Omicron has rapidly replaced the circulating variants, the mAbs arsenal should be updated accordingly. Clearly, surveillance of SARS-CoV-2 evolution over time and in different geographical areas remains a priority to adapt our defences against the pandemic. This work was partly funded by the European Commission under HORIZON-HLTH-2021-CORONA-01, Project EuCARE, grant agreement N. 101046016. MZ reports consultancy for ViiV Healthcare, Gilead Sciences, Janssen-Cilag, Theratechnologies, and Merck Sharp and Dohme (MSD) and grants for his institution from ViiV Healthcare, Theratechnologies, and Gilead Sciences outside the submitted work. BR received support for travel to meetings from Abbvie, Gilead Sciences, Janssen-Cilag, MSD, ViiV Healthcare, and Bristol Myers Squibb and fees for attending advisory boards and speaker's honoraria from Abbvie, Gilead Sciences, Janssen-Cilag, MSD, ViiV Healthcare, and Bristol-Myers Squibb. All other authors have no conflicts to declare. IV, MZ, DF, and MRG conceived the idea for this work. FD, LF, VM, AL, and ES performed the experiments. FD, LF, BR, and IV contributed to the data analysis. VM, AL, ES, GZ, MRG, BR, and DF collected the samples and provided the virus lineages for this work. IV, FD, and MZ wrote the paper. All authors contributed to the revision and approved the final version of the manuscript. We would like to thank Dr. Cesira Nencioni and Dr. Alessandro Lanari for their support in this study. The following are the Supplementary data to this article: Download .docx (.23 MB) Help with docx files Multimedia component 1 Download .docx (.01 MB) Help with docx files Multimedia component 2 Download .docx (.02 MB) Help with docx files Multimedia component 3" @default.
• W4220657204 created "2022-04-03" @default.
• W4220657204 creator A5002487044 @default.
• W4220657204 creator A5009479812 @default.
• W4220657204 creator A5012791067 @default.
• W4220657204 creator A5018107636 @default.
• W4220657204 creator A5032859619 @default.
• W4220657204 creator A5046931461 @default.
• W4220657204 creator A5050931425 @default.
• W4220657204 creator A5052006950 @default.
• W4220657204 creator A5067155251 @default.
• W4220657204 creator A5075069140 @default.
• W4220657204 creator A5090301614 @default.
• W4220657204 date "2022-07-01" @default.
• W4220657204 modified "2023-10-14" @default.
• W4220657204 title "Impact of SARS-CoV-2 omicron BA.1 and delta AY.4.2 variants on the neutralization by sera of patients treated with different authorized monoclonal antibodies" @default.
• W4220657204 cites W3044726785 @default.
• W4220657204 cites W3161156876 @default.
• W4220657204 cites W3165479483 @default.
• W4220657204 cites W3182094313 @default.
• W4220657204 cites W3214258211 @default.
• W4220657204 cites W4200047841 @default.
• W4220657204 cites W4221116249 @default.
• W4220657204 cites W4226087845 @default.
• W4220657204 doi "https://doi.org/10.1016/j.cmi.2022.03.005" @default.
• W4220657204 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35304279" @default.
• W4220657204 hasPublicationYear "2022" @default.
• W4220657204 type Work @default.
• W4220657204 citedByCount "5" @default.
• W4220657204 countsByYear W42206572042022 @default.
• W4220657204 countsByYear W42206572042023 @default.
• W4220657204 crossrefType "journal-article" @default.
• W4220657204 hasAuthorship W4220657204A5002487044 @default.
• W4220657204 hasAuthorship W4220657204A5009479812 @default.
• W4220657204 hasAuthorship W4220657204A5012791067 @default.
• W4220657204 hasAuthorship W4220657204A5018107636 @default.
• W4220657204 hasAuthorship W4220657204A5032859619 @default.
• W4220657204 hasAuthorship W4220657204A5046931461 @default.
• W4220657204 hasAuthorship W4220657204A5050931425 @default.
• W4220657204 hasAuthorship W4220657204A5052006950 @default.
• W4220657204 hasAuthorship W4220657204A5067155251 @default.
• W4220657204 hasAuthorship W4220657204A5075069140 @default.
• W4220657204 hasAuthorship W4220657204A5090301614 @default.
• W4220657204 hasBestOaLocation W42206572041 @default.
• W4220657204 hasConcept C116675565 @default.
• W4220657204 hasConcept C121332964 @default.
• W4220657204 hasConcept C1276947 @default.
• W4220657204 hasConcept C14086860 @default.
• W4220657204 hasConcept C142724271 @default.
• W4220657204 hasConcept C159047783 @default.
• W4220657204 hasConcept C159654299 @default.
• W4220657204 hasConcept C203014093 @default.
• W4220657204 hasConcept C2522874641 @default.
• W4220657204 hasConcept C2779134260 @default.
• W4220657204 hasConcept C3006700255 @default.
• W4220657204 hasConcept C3007834351 @default.
• W4220657204 hasConcept C3008058167 @default.
• W4220657204 hasConcept C5072461 @default.
• W4220657204 hasConcept C524204448 @default.
• W4220657204 hasConcept C542903549 @default.
• W4220657204 hasConcept C71924100 @default.
• W4220657204 hasConcept C86803240 @default.
• W4220657204 hasConceptScore W4220657204C116675565 @default.
• W4220657204 hasConceptScore W4220657204C121332964 @default.
• W4220657204 hasConceptScore W4220657204C1276947 @default.
• W4220657204 hasConceptScore W4220657204C14086860 @default.
• W4220657204 hasConceptScore W4220657204C142724271 @default.
• W4220657204 hasConceptScore W4220657204C159047783 @default.
• W4220657204 hasConceptScore W4220657204C159654299 @default.
• W4220657204 hasConceptScore W4220657204C203014093 @default.
• W4220657204 hasConceptScore W4220657204C2522874641 @default.
• W4220657204 hasConceptScore W4220657204C2779134260 @default.
• W4220657204 hasConceptScore W4220657204C3006700255 @default.
• W4220657204 hasConceptScore W4220657204C3007834351 @default.
• W4220657204 hasConceptScore W4220657204C3008058167 @default.
• W4220657204 hasConceptScore W4220657204C5072461 @default.
• W4220657204 hasConceptScore W4220657204C524204448 @default.
• W4220657204 hasConceptScore W4220657204C542903549 @default.
• W4220657204 hasConceptScore W4220657204C71924100 @default.
• W4220657204 hasConceptScore W4220657204C86803240 @default.
• W4220657204 hasFunder F4320307115 @default.
• W4220657204 hasFunder F4320308573 @default.
• W4220657204 hasFunder F4320309117 @default.
• W4220657204 hasFunder F4320320300 @default.
• W4220657204 hasFunder F4320332932 @default.
• W4220657204 hasFunder F4320338413 @default.
• W4220657204 hasIssue "7" @default.
• W4220657204 hasLocation W42206572041 @default.
• W4220657204 hasLocation W42206572042 @default.
• W4220657204 hasLocation W42206572043 @default.
• W4220657204 hasLocation W42206572044 @default.
• W4220657204 hasOpenAccess W4220657204 @default.
• W4220657204 hasPrimaryLocation W42206572041 @default.
• W4220657204 hasRelatedWork W3009669391 @default.
• W4220657204 hasRelatedWork W3036305013 @default.
• W4220657204 hasRelatedWork W3036314732 @default.
• W4220657204 hasRelatedWork W3127693599 @default.
• W4220657204 hasRelatedWork W4200329650 @default.

• next